MKC-Quatsomes: a stable nanovesicle platform for bio-imaging and drug-delivery applications

Quatsomes are outstanding new lipid-based nanovesicles that are highly homogeneous and stable in different media for years, but the composition must be carefully chosen to avoid any potentially toxic side effects in in vivo applications. To this end, we have developed and studied a novel type of Quatsomes composed of cholesterol and myristalkonium chloride (MKC), the latter being extensively used as antimicrobial preservative in many ophthalmic and parenteral formulations on the EU and USA market. We have synthesized these novel MKC-Quatsomes in different media that are suitable for parenteral administration, and confirmed their stability in these media for 18 months, as well as the stability in human serum for 24 hours. Biodistribution assays were performed after intravenous injection of fluorescently labeled MKC-Quatsomes in live mice bearing xenografted colorectal tumors, showing nanovesicle accumulation in tumors, liver, spleen, and kidneys. No histological alteration or toxicity was observed in any of these organs. New lipid-based nanovesicles composed of myristalkonium chloride (MKC) and cholesterol have been developed and labeled with a fluorescent dye for biodistribution studies. These vesicles, called MKC-Quatsomes, are stable in human serum and have not produced any histological alterations after injection in mice. [Display omitted]